Freba Farhat, MD
Dermatology · Washington, DCNPI 1992116016
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,338 of the $9,289 with a category attached, or 68.2%. UCB, Inc. accounts for 85.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $7,727 and has fallen 95.5% since, to $349 in 2025.
Across 35 payments — averaging $265.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$8K
- AbbVie$331
- Johnson & Johnson$320
- Sanofi$269
- E.r. Squibb & Sons, L.L.C.$117
- Regeneron Healthcare Solutions, Inc.$113
- plus $185 from 5 others
What the payments were for
- Consulting fees$6,33868%
- Travel & lodging$1,07512%
- Food & beverage$1,61617%
- Education$2603%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 15 | $7,954 |
| AbbVie | 4 | $331 |
| Johnson & Johnson | 6 | $320 |
| Sanofi | 3 | $269 |
| E.r. Squibb & Sons, L.L.C. | 1 | $117 |
| Regeneron Healthcare Solutions, Inc. | 1 | $113 |
| Regeneron | 1 | $82 |
| Janssen Scientific Affairs, LLC | 1 | $39 |
| Integra Lifesciences Corporation | 1 | $32 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,289 in reported general payments places this provider in the 65th percentile of 73 dermatology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clindamycin Phosphate | 13 | $625 |
| Ammonium Lactate | 12 | $333 |
| Hydrocortisone | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Washington
- Jonathan SilverbergWashington$4.5M
- Adam FriedmanWashington$2.2M
- Terrence KeaneyWashington$1.1M
- Candrice HeathWashington$168K
- Agnes ChangWashington$109K
- Todd PerkinsWashington$102K
- Karl SaardiWashington$101K
- Noelle SherberWashington$96K
- Yolanda HolmesWashington$80K
- Cheri FreyWashington$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.